PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
MiraeING runs a stable core banking SWIFT solutions business, but non-operating swings tied to group M&A and equity stakes have driven four straight years of net losses attributable to owners.
2025 operating profit improved to KRW 3.8bn, yet owners' net income stayed negative at -KRW 2.6bn, a fourth straight year of losses
In March 2026, Stella Private Equity acquired control of MiraeING and four affiliated listed firms for KRW 120bn
In Q2 2026 operating profit was KRW 1.27bn but the net loss widened sharply to -KRW 2.44bn, showing non-operating items dominate results
Operating cash flow stayed positive throughout (KRW 5.1-7.2bn per year), indicating the core business cash generation remains intact
MiraeING still holds a 10.99% stake in Fantagio, keeping it exposed to entertainment-affiliate risk
MiraeING was established in 1971 and listed on the KOSPI in 1999, and today its core business is financial IT solutions.
Its main offerings are the SWIFT management solution eNisis, the anti-money-laundering compliance solution SafeWatch, and the FX trading solution Summit, sold mainly to Korean banks including Hana Bank, Shinhan Bank and Woori Bank.
The company built its position on proprietary SWIFT-related technology, supplying maintenance and solutions even to overseas branches of Korean banks. Alongside financial solutions, it also runs a B&E business unit and a real-estate leasing and management operation.
In 2023, the solutions segment generated roughly KRW 13.03bn in revenue, up about 1.5% from KRW 12.83bn a year earlier.
On the ownership side, control changed hands in March 2026 when Stella Private Equity became the largest shareholder through a package deal covering MiraeING and four affiliated listed companies (Incon, K-Bio Company, Humasis and Billance) for a 22.28% stake worth KRW 120bn.
Entertainment and bio-related affiliates such as Fantagio, Kyungnam Pharm and Ascendio were excluded from the sale and remain under former chairman Namgung Gyeon's control.
However, MiraeING itself still holds a 10.99% stake in Fantagio as its largest shareholder, keeping a residual equity link even after the group split.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩3.6B | ₩1.2B | 33.6% |
| 2025Q3 | ₩3.9B | ₩1.2B | 30.9% |
| 2025Q4 | ₩4.3B | ₩1.5B | 33.8% |
| 2026Q1 | ₩3.7B | ₩800M | 21.8% |
| 2026Q2 | ₩2.5B | ₩100M | 5.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩12.8B | ₩3.1B | -₩3B | 24.2% | −4.4% | 40.4% |
| 2023 | ₩13B | ₩3.2B | -₩9.3B | 24.8% | −16.0% | 45.3% |
| 2024 | ₩11.7B | ₩2B | -₩8B | 17.2% | −15.8% | 46.9% |
| 2025 | ₩14.1B | ₩3.8B | -₩2.6B | 26.9% | −5.3% | 45.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue eased from KRW 12.8bn in 2022 to KRW 13.0bn in 2023 and KRW 11.7bn in 2024, before rebounding to KRW 14.1bn in 2025, the highest of the past four years.
The operating margin fluctuated between 17.2% and 26.9% over 2022-2025, and 2025 operating profit rose clearly to KRW 3.8bn from KRW 2.0bn in 2024.
Net income attributable to owners, however, stayed negative for four straight years: -KRW 3.03bn in 2022, -KRW 9.30bn in 2023, -KRW 8.04bn in 2024 and -KRW 2.60bn in 2025 — a structure where operating profit is consistently positive while the bottom line remains in the red.
Operating cash flow held steady and positive at KRW 5.1-7.2bn each year over the same period, suggesting the net losses stem not from weak core cash generation but from non-operating items such as equity-method or valuation losses.
On a quarterly basis, the net loss of -KRW 1.42bn in Q3 2025 narrowed to a small profit of KRW 0.03bn in Q4 2025, and widened further into profit at KRW 0.82bn in Q1 2026.
In Q2 2026, however, operating profit was only KRW 1.27bn while the net loss ballooned to -KRW 2.44bn, swinging back into the red and reaffirming that non-operating volatility, not the core business, drives the bottom line.
As a result, the sum of owners' net income over the trailing four quarters (Q3 2025-Q2 2026) was roughly -KRW 3.0bn, keeping the annualized trend in loss territory.
Owners' equity steadily declined from KRW 69.4bn in 2022 to KRW 48.6bn in 2025, reflecting years of accumulated losses eroding capital in the absence of dividends, while the debt ratio stayed within a 40-47% range, indicating no excessive leverage relative to the company's size.
SWIFT infrastructure at Korean banks is essential backbone for cross-border financial transactions, and demand for proprietary SWIFT-based cash management solutions has grown alongside the increasing globalization of Korean corporations.
MiraeING holds a specialized position built on being the first to introduce SWIFT-related systems domestically, supplying maintenance and management solutions to most Korean banks and their overseas branches.
That said, the financial IT infrastructure market is concentrated among a small number of bank clients, making quarterly results sensitive to shifts in any single bank's IT budget or project schedule.
Separately, at the group level, MiraeING has expanded via M&A into unrelated industries such as healthcare (Humasis) and entertainment (Fantagio and others) in recent years, but many of the acquired companies have posted operating losses, weighing on the group's overall profitability.
The March 2026 change of control to Stella PE can be read as an attempt to untangle this increasingly complex governance structure, and shareholder-friendly steps such as treasury share retirements have followed.
Looking at the core financial-solutions business alone, steady demand for bank digitalization and SWIFT infrastructure upgrades suggests the company retains a stable position in a relatively low-competition niche.
Following the March 2026 change of control, Stella PE announced completion of a second installment payment in early July as it proceeds with the remaining balance of the acquisition. Management has laid out plans to continue investing to create synergies among affiliates and secure new growth drivers.
In practice, a KRW 10bn rights offering was carried out at affiliate Billance in April, followed by participation in a capital raise at Incon, putting Stella PE at the forefront of affiliate management.
On the governance side, shareholder-friendly actions have continued, including the retirement of 6 million treasury shares (4.6% of shares outstanding) at Humasis in March and a separate retirement of 1.55 million MiraeING shares (5.4% of shares outstanding) in May.
However, entertainment and bio affiliates excluded from the acquisition package — Fantagio, Kyungnam Pharm and Ascendio — remain under former chairman Namgung Gyeon's control, leaving the fate of MiraeING's own 10.99% Fantagio stake as a separate open issue.
The company has not yet issued formal revenue or profit guidance, and future results are likely to hinge on the pace of governance restructuring under the Stella PE regime and whether affiliate-level profitability improves.
The share price trades below the company's book value per share, placing it in a discount range relative to net asset value. The company has not paid a meaningful cash dividend in recent years, so shareholder returns via dividends remain limited.
Looking at the trailing four quarters, operating profit has been generated consistently, but net income has swung between losses and profits depending on non-operating volatility, which complicates the reading of conventional earnings multiples.
The continuation of shareholder-friendly actions such as treasury share retirements since the change of control to Stella PE is a factor that could influence valuation going forward.
Ultimately, how the market values the stock is likely to reflect both changes in net asset value and whether earnings stability improves following the governance overhaul.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The bank-facing SWIFT solutions business rests on long-standing relationships with major banks such as Hana, Shinhan and Woori, built on a technical position derived from being an early domestic adopter.
The operating margin holding in a 17-27% range from 2022 to 2025 shows the core earnings structure has been relatively solid. Operating cash flow also stayed positive across all four years, indicating the core business's cash generation has not been impaired.
Stella PE, which took control in March 2026, followed the retirement of 6 million Humasis treasury shares with a decision in May to retire 1.55 million MiraeING shares (5.4% of shares outstanding) as well.
Taking concrete retirement action early in the ownership transition is cited as a sign of commitment to accountable management. Whether similar shareholder-friendly policies spread across the broader affiliate group going forward is worth watching.
The debt ratio has stayed within a 40-47% range from 2022 to 2025, and no sign of excessive borrowing relative to the size of the balance sheet is observed each year. Despite the run of net losses, the financial structure itself has not deteriorated sharply.
Despite consistently positive operating profit, owners' net income posted a loss every year from 2022 to 2025. This suggests non-operating items such as equity-method or valuation losses have continually eroded results, and owners' equity fell from KRW 69.4bn in 2022 to KRW 48.6bn in 2025. Unless the underlying cause is resolved, the pattern of net losses could persist.
The MiraeING group is intertwined with numerous listed affiliates beyond Humasis, Incon, K-Bio Company and Billance, including Fantagio, Kyungnam Pharm and Ascendio.
The Q2 2026 case, where operating profit was KRW 1.27bn but the net loss widened to -KRW 2.44bn, shows how swings in affiliate stakes and earnings can heavily shake overall results. This structure reduces the predictability of reported earnings.
It has been only a short time since Stella PE became the largest shareholder in March 2026, and balance payments and affiliate integration work are still in progress.
Unresolved issues remain, including how relationships with affiliates still controlled by former chairman Namgung Gyeon (Fantagio, Kyungnam Pharm, Ascendio) will be settled and what will happen to MiraeING's own Fantagio stake. It will take time for the new management's strategy to fully take hold.
MiraeING holds a 10.99% stake in Fantagio as its largest shareholder, and Fantagio's share price has swung sharply amid a tax controversy involving its talent and weak operating results.
With KOSDAQ's market-cap delisting threshold tightened, the possibility of Fantagio being designated an administrative issue cannot be ruled out, and swings in the value of this stake could again affect MiraeING's results.
Since 2023, the MiraeING group has acquired a range of companies in unrelated industries including Humasis, Kyungnam Pharm, Billance and Ascendio, several of which have posted operating losses.
If affiliate underperformance persists, the burden of capital raises or financial support could spill over to MiraeING as well.
Stella PE's acquisition is a package deal bundling several listed companies, with installment and balance payments and governance restructuring proceeding sequentially through 2026.
This process could increase related-party transactions such as intra-group capital raises and share transfers, so minority shareholders need to continue monitoring the structure and terms of these deals.
Check the Q3 2026 report for whether the operating margin holds and the scale of non-operating items (equity-method/valuation gains or losses), to see whether a sharp net-loss swing like Q2 2026 recurs.
Watch for disclosures on whether Stella PE completes the final balance payment for its five-company acquisition package and on further governance restructuring (affiliate equity realignment, capital raises, etc.).
Monitor the outcome of Fantagio's tax investigation and any KOSDAQ listing-maintenance review, as this could directly affect the value of MiraeING's 10.99% Fantagio stake.
Check for any additional MiraeING-level shareholder-return actions (share buybacks/retirements) or changes to dividend policy.
MiraeING generates positive operating profit and operating cash flow every year on the back of a stable, niche core business in bank-facing SWIFT solutions.
Yet owners' net income posted losses in every year from 2022 through 2025, and in Q2 2026 the net loss again far exceeded operating profit, underscoring a structure where non-operating volatility drives the bottom line.
The change of controlling shareholder to Stella PE in March 2026 kicked off shareholder-return measures such as treasury share retirements, but the balance-payment execution and governance restructuring for the five-company package deal remain ongoing.
The relationship with entertainment and bio affiliates excluded from the sale — Fantagio, Kyungnam Pharm and Ascendio — and the fate of MiraeING's own residual stake in Fantagio, are separate variables that warrant continued attention.
Overall, this stock currently sits at the intersection of stable core cash generation, unstable non-operating earnings, and an ownership transition that is still in progress.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.